Agendia
Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer
Premium
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.
Agendia Offering AI-Enabled Genomic Test for Breast Cancer in Brazil as it Eyes Global Market
Premium
The firm is offering access in Brazil to a digital assay that provides genomic insights using technology developed in a collaboration with computational pathology firm Paige.
Agendia to Distribute Inivata Liquid Biopsy Breast Cancer Test in North America, Europe
Agendia will receive co-exclusive rights to distribute Inivata's RaDaR assay for minimal residual disease and relapse detection in Europe and North America.
FLEX will include full transcriptome data paired with 800 data points from 10,000 patients, offering researchers the chance to study diverse patient subsets.
Jun 12, 2020
Dec 10, 2018
SABCS 2018 Features Molecular Diagnostics Research
Nov 16, 2018
Jul 25, 2018